1. Medtech Insight
  2. >>Policy & Regulation

Promise Of MolDx Program For Molecular Tests Unfulfilled, Labs Say

Benefits to test makers and users from the Medicare MolDx program have not been fully reaped, diagnostic reimbursement experts said at a recent Avalere summit.

The promise of Medicare’s MolDx program to provide greater reimbursement consistency and to fully reflect the value of molecular diagnostics has yet to be fulfilled, laboratory representatives argued at a diagnostics summit last month.

The Molecular Diagnostic Services, or MolDx, process for assessing CPT codes for reimbursement of lab tests “is taking more time...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

Cardiology And PTA Procedures In Germany’s Expanded Hybrid DRGs List 2026

 
• By Ashley Yeo

2026 reimbursement calculations for the list of hybrid DRGs – a mechanism to incentivize day cases over inpatient surgery – will be issued in few weeks’ time. The medtech industry has made its demands known.

Deals Shaping The Medtech And Diagnostics Industries, July 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during July 2025. Data courtesy of Biomedtracker.

Biden-Era Device Trial Snapshot Pilot Halted Amid DEI Policy Shift

 
• By Elizabeth Orr

The FDA's Device Clinical Trial Snapshot Pilot, aimed at increasing trial transparency and diversity, has been canceled following President Trump’s anti-DEI executive order. Critics warn this may hinder trial transparency, impacting public health and demographic data accessibility.